中华皮肤科杂志

• 论著 • 上一篇    下一篇

糖皮质激素上调系统性红斑狼疮患者外周血CD4+CD25+T细胞CD62L的表达

谭国珍1, 彭辉2, 毛越苹1, 曾凡钦1   

  1. 1. 中山大学附属第二医院皮肤科, 广州, 510120;
    2. 中山大学中山医学院免疫学教研室
  • 收稿日期:2006-07-03 出版日期:2007-06-15 发布日期:2007-06-15
  • 通讯作者: 曾凡钦,email:shenzqtgz@yahoo.com.cn E-mail:shenzqtgz@yahoo.com.cn
  • 基金资助:
    广东省科技计划基金(2004B31201004)

Glucocorticoids treatment upregulates the expression of CD62L in CD4+CD25+T cells in peripheral blood monocytes of patients with systemic lupus erythematosus

TAN Guo-zhen1, PENG Hui2, MAO Yue-ping1, ZENG Fan-qin1   

  1. Department of Dermatology, Second Affiliated Hospital of Zhongshan University, Guangzhou 510120, China
  • Received:2006-07-03 Online:2007-06-15 Published:2007-06-15

PDF (PC)

115

赞

摘要： 目的 探讨糖皮质激素(简称激素)治疗对系统性红斑狼疮(SLE)患者外周血CD4+CD25+T细胞(调节性T细胞)亚群CD62L表达的影响。方法 采用流式细胞仪检测了10例初发未经治疗的SLE患者和25例经激素治疗后的SLE患者外周血CD4+CD25+T细胞亚群CD62L的表达,并与12例正常人对照组相比较。结果 未经治疗的初发SLE患者CD62L+和CD62L-的CD4+CD25+T细胞均较健康对照组明显减少。激素治疗后,SLE患者外周血CD4+CD25+CD62L+T细胞显著升高,而且与糖皮质激素剂量有关。大剂量激素治疗组CD4+CD25+CD62L+T细胞显著高于未治疗组和正常人对照组,但小剂量激素治疗组CD4+CD25+CD62L+T细胞仅高于未治疗组。然而无论小剂量激素治疗组还是大剂量激素治疗组的CD4+CD25+CD62L-T细胞与正常人对照组比较差异均无统计学意义。SLE患者外周血CD4+CD25+CD62L+ T细胞与疾病活动指数成负相关。结论 糖皮质激素可能上调SLE患者外周血CD4+CD25+CD62L+T细胞的生成.促进外周免疫耐受,从而缓解病情。

关键词: 红斑狼疮, 系统性, 糖皮质激素类, T淋巴细胞

Abstract: Objective To investigate the effect of glucocorticoids(GC)treatment on the expression of CD62L in CD4+ CD25+ T cells in peripheral blood monocytes(PBMC)of patients with systemic lupus erythematosus(SLE).Methods Flow cytometry was used to detect the expression of CD62L in CD4+ CD25+ T cells in PBMC of 35 SLE patients(10 untreated,25 treated with GC)and 12 normal human controls.Results The frequencies of both CD4+CD25+ CD62L+ T cells and CD4+CD25+ CD62L- T cells were signifi-cantly decreased in untreated SLE patients compared with the controls[(4.12±3.68)% vs(9.27±4.44)%,P<0.05 and(1.15±0.99)% vs(4.25±2.21)%,P<0.05].The frequency of CD4+CD25+ CD62L+T cells in SLE patients treated with GC increased greatly;this increase was related to the dose of GC.The frequency of CD4+ CD25+ CD62L+T cells in SLE patients treated with high-dose GC was higher than that in untreated SLE patients and normal controls[(14.84±6.41)% vs(4.12±3.68)%,P<0.05 and(14.84±6.41)vs(9.27±4.44)%,P<0.05],while that in SLE patients treated with low-dose GC was only higher than that in untreated SLE patients[(9.07±5.27)% vs(4.12±3.68)%,P<0.05)]. No difference was found in the frequency of CD4+CD25+ CD62L-T cells between either SLE patients treated with high-dose GC or those with low-dose GC and the controls.The frequency of CD4+ CD25+CD62L+T cells had a negative correlation with disease activity of SLE(SLEDAI).Conclusion GC treatment can decrease the disease activity in SLE by upregulating the generation of CD4+CD25+ T cells,especially CD4+ CD25+ CD62L+T cells,hence promoting peripheral immunotolerance.

Key words: Lupus erythematosus, systemic, Glucocorticoids, T-lymphocytes